Biohaven Ltd. (NYSE:BHVN) Receives Consensus Rating of “Moderate Buy” from Analysts

Shares of Biohaven Ltd. (NYSE:BHVN) have earned a consensus rating of “Moderate Buy” from the seventeen brokerages that are currently covering the stock, Marketbeat reports. One analyst has rated the stock with a sell rating, five have issued a hold rating, nine have given a buy rating and two have assigned a strong buy rating to the company. The average 1 year price target among analysts that have updated their coverage on the stock in the last year is $22.2667.

Several research firms recently issued reports on BHVN. Raymond James Financial restated a “strong-buy” rating on shares of Biohaven in a research note on Monday, March 9th. The Goldman Sachs Group upgraded Biohaven to a “strong-buy” rating in a research note on Friday, February 6th. Wall Street Zen downgraded Biohaven from a “sell” rating to a “strong sell” rating in a research note on Sunday, April 26th. Citigroup boosted their price target on Biohaven from $14.00 to $17.00 and gave the company a “buy” rating in a research note on Thursday, April 2nd. Finally, Morgan Stanley reduced their price target on Biohaven from $21.00 to $18.00 and set an “overweight” rating for the company in a research note on Wednesday.

Biohaven Stock Performance

Shares of NYSE BHVN opened at $8.74 on Monday. The company has a current ratio of 7.41, a quick ratio of 7.41 and a debt-to-equity ratio of 1.87. Biohaven has a 12 month low of $7.48 and a 12 month high of $18.57. The stock has a 50 day moving average of $9.57 and a 200-day moving average of $10.65. The company has a market capitalization of $1.32 billion, a P/E ratio of -1.54 and a beta of 1.32.

Biohaven (NYSE:BHVN) last issued its earnings results on Monday, May 4th. The company reported ($0.88) EPS for the quarter, missing the consensus estimate of ($0.86) by ($0.02). As a group, equities research analysts predict that Biohaven will post -2.97 EPS for the current year.

Institutional Trading of Biohaven

Several institutional investors have recently added to or reduced their stakes in BHVN. Suvretta Capital Management LLC boosted its stake in Biohaven by 83.0% in the 4th quarter. Suvretta Capital Management LLC now owns 10,286,937 shares of the company’s stock valued at $116,140,000 after purchasing an additional 4,666,666 shares during the period. Infinitum Asset Management LLC raised its holdings in Biohaven by 267.6% in the 4th quarter. Infinitum Asset Management LLC now owns 6,250,000 shares of the company’s stock valued at $70,562,000 after acquiring an additional 4,550,000 shares in the last quarter. Stifel Financial Corp raised its holdings in Biohaven by 50.3% in the 4th quarter. Stifel Financial Corp now owns 9,939,856 shares of the company’s stock valued at $112,221,000 after acquiring an additional 3,328,506 shares in the last quarter. Schonfeld Strategic Advisors LLC raised its holdings in Biohaven by 3,829.9% in the 4th quarter. Schonfeld Strategic Advisors LLC now owns 1,606,777 shares of the company’s stock valued at $18,141,000 after acquiring an additional 1,565,891 shares in the last quarter. Finally, Vanguard Group Inc. raised its holdings in Biohaven by 52.9% in the 4th quarter. Vanguard Group Inc. now owns 4,395,946 shares of the company’s stock valued at $49,630,000 after acquiring an additional 1,520,756 shares in the last quarter. 88.78% of the stock is currently owned by institutional investors.

Biohaven Company Profile

Biohaven Ltd. (NYSE BHVN) is a clinical-stage biopharmaceutical company dedicated to developing and commercializing therapies for neurological and neurovascular diseases. Founded in 2013 as a spin-out from Yale University, Biohaven focuses on addressing high-unmet medical needs through innovative small-molecule and peptide-based platforms. The company is headquartered in New Haven, Connecticut, and maintains research activities across the United States, with collaborative ties in Europe and Asia via strategic partnerships.

The company’s most advanced program centers on calcitonin gene-related peptide (CGRP) receptor antagonists for the acute and preventive treatment of migraine.